Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apramycin Lung PK and Safety in Healthy Adults
NCT05590728Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of apramycin in bacterial infection (5 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to 8 h of Total Apramycin in Epithelial Lining Fluid and Alveolar Macrophage, Area Under the Concentration-time Curve From Time Zero to Infinity of Total Apramycin in ELF and AM and 13 more. Started Jun 2023; status: completed.
02
Drugs
apramycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05590728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590728.